1. Signaling Pathways
  2. Apoptosis
  3. Apoptosis

Apoptosis

Apoptosis

Apoptosis is a distinctive form of cell death exhibiting specific morphological and biochemical characteristics, including cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and exposure of specific phagocytosis signaling molecules on the cell surface. Cells undergoing apoptosis differ from those dying through necrosis. Necrotic cells are usually recognized by the immune system as a danger signal and, thus, resulting in inflammation; in contrast, apoptotic death is quiet and orderly.

There are two major pathways of apoptotic cell death induction: The intrinsic pathway, also called the Bcl-2-regulated or mitochondrial pathway, is activated by various developmental cues or cytotoxic insults, such as viral infection, DNA damage and growth-factor deprivation, and is strictly controlled by the BCL-2 family of proteins. The extrinsic or death-receptor pathway is triggered by ligation of death receptors (members of the tumor necrosis factor (TNF) receptor family, such as Fas or TNF receptor-1 (TNFR1)) that contain an intracellular death domain, which can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface. This recruitment causes subsequent activation of downstream (effector) caspases, such as caspase-3, -6 or -7, without any involvement of the BCL-2 family.

Studies suggest that alterations in cell survival contribute to the pathogenesis of a number of human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome). Treatments designed to specifically alter the apoptotic threshold may have the potential to change the natural progression of some of these diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146189
    Topoisomerase II inhibitor 9
    Inducer
    Topoisomerase II inhibitor 9 (Compound 19b) is a Topo II inhibitor with an IC50 of 0.97 μM. Topoisomerase II inhibitor 9 is also a classical DNA-intercalator with an IC50 of 43.51 μM. Topoisomerase II inhibitor 9 arrests the cell cycle at the G2/M phase and induces apoptosis in Hep G‐2 cells.
    Topoisomerase II inhibitor 9
  • HY-N1219
    Stephanine
    Inducer
    Stephanine ((-)-Stephanine) is an isoquinoline aporphine-type alkaloid. Stephanine induce apoptosis through the reverse of mitotic exit. Stephanine exhibits Antiplasmodial activity. Stephanine can be used for the research of stomach pain, abdominal pain, arthritis and cancer.
    Stephanine
  • HY-175700
    YCJ-02
    Inducer
    YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC).
    YCJ-02
  • HY-128749AR
    D-Glucaric acid tetrahydrate (Standard)
    Inducer
    D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases.
    D-Glucaric acid tetrahydrate (Standard)
  • HY-B0124S3
    Zonisamide-15N,d4
    Zonisamide-15N,d4 is the 15N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide-<sup>15</sup>N,d<sub>4</sub>
  • HY-P0036A
    Octreotide dihydrochloride
    Inducer
    Octreotide (SMS 201-995) hydrochloride is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
    Octreotide dihydrochloride
  • HY-155570
    Anticancer agent 137
    Inducer
    Anticancer agent 137 (8q) is a potent PI3k inhibitor. Anticancer agent 137 has broad-spectrum anticancer activity. Anticancer agent 137 induces G2/M cell cycle arrest and apoptosis. Anticancer agent 137 increases cleaved PARP, caspase 3, and 7. Anticancer agent 137 can be used in research of cancer.
    Anticancer agent 137
  • HY-162462
    Antitumor agent-151
    Inducer
    Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis.
    Antitumor agent-151
  • HY-146218
    MMP-9-IN-5
    Inducer
    MMP-9-IN-5 is a MMP-9 inhibitor (IC50: 4.49 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-5 also inhibits AKT activity (IC50: 1.34 nM). MMP-9-IN-5 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-5 can be used in the research of cancers.
    MMP-9-IN-5
  • HY-178010
    Mcl-1-IN-17
    Inhibitor
    Mcl-1-IN-17 (Compound 25) is an orally active Myeloid Cell Leukemia 1 (Mcl-1) inhibitor with a Ki < 0.08  nM. Mcl-1-IN-17 has a significant antiproliferative activity (GI50s of 39 and 105  nM for H929 and A427 cells, respectively) and inhibits cell apoptosis. Mcl-1-IN-17 can be used for hematological and solid cancers research.
    Mcl-1-IN-17
  • HY-N0763R
    Angelicin (Standard)
    Inducer
    Angelicin (Standard) is the analytical standard of Angelicin. This product is intended for research and analytical applications. Angelicin is a natural tricyclic aromatic hydrocarbon compound that is structurally related to psoralen and has anti-cancer, anti-inflammatory, anti-viral and other activities. Cytotoxic, IC50: 49.56 μM; inhibits MHV-68, IC50: 5.39 μg/ml (28.95 μM).
    Angelicin (Standard)
  • HY-155972A
    CRM1-IN-2
    Inducer
    CRM1-IN-2 (Compound KL2) is a noncovalent CRM1 inhibitor. CRM1-IN-2 localizes CRM1 in the nuclear periphery, depletes nuclear CRM1, and inhibits CRM1-mediated nuclear export. CRM1-IN-2 inhibits growth of colorectal cancer cells, and induces apoptosis.
    CRM1-IN-2
  • HY-175757
    HsClpP activator-2
    Inducer
    HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC).
    HsClpP activator-2
  • HY-178941
    DHODH-IN-32
    Inducer
    DHODH-IN-32 (Compound A1) is a DHODH inhibitor. DHODH-IN-32 shows significant cytotoxicity against NCI-60 cell lines, especially being sensitive to breast cancer, prostate cancer and leukemia cell lines. DHODH-IN-32 can induce cell apoptosis by activating the Caspase pathway. DHODH-IN-32 causes G0/G1 phase cell cycle arrest and inhibits cellular metabolism by ROS. DHODH-IN-32 exhibits significant anti-tumor properties in mouse breast cancer models. DHODH-IN-32 can be used for the study of breast cancer.
    DHODH-IN-32
  • HY-169797
    STAT3-IN-38
    Activator
    STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33  µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells.
    STAT3-IN-38
  • HY-N10798
    Kusunokinin
    Inducer
    Kusunokinin ((-)-Kusunokinin) is a nature product that could be isolated form P. nigrum. Kusunokinin has anticancer activity. Kusunokinin arrests cell cycle at G2/M phase and induce apoptosis.
    Kusunokinin
  • HY-178431
    MT-44
    Inducer
    MT-44 is a highly selective and potent mTOR inhibitor with an IC50 of 49.4 nM. MT-44 can inhibit cancer cells proliferation, migration and invasion. MT-44 can induce cells apoptosis and ROS production and cause G2/M phase arrest. MT-44 can activate the cGAS/STING pathway. MT-44 can be used for the research of cancer, such as triple-negative breast cancer.
    MT-44
  • HY-P5345
    KLA peptide
    Inducer
    KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
    KLA peptide
  • HY-161338
    Tubulin polymerization-IN-61
    Inducer
    Tubulin polymerization-IN-61 (Compound 9a) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-61 destroys the microtubule skeleton, blocks the cell cycle in G2/M phase, induces Apoptosis, and inhibits cancer cell migration and colony formation. Tubulin polymerization-IN-61 shows antitumor activity in vivo against 4T1 xenograft model.
    Tubulin polymerization-IN-61
  • HY-183788
    EGFR-IN-212
    Inducer
    EGFR-IN-212 is an EGFR inhibitor with human IC50 values of 1.83 μM. EGFR-IN-212 reduces EGFR mRNA expression and induces apoptosis. EGFR-IN-212 can be used for the research of non-small cell lung carcinoma.
    EGFR-IN-212
Cat. No. Product Name / Synonyms Application Reactivity